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Introduction
IFNg is the pivotal mediator in the murine model of
primary HLH. Mice given repeated injection with the
TLR9 agonist, CpG-containing oligodeoxynucleotides,
develop pathology resembling the human disease, sHLH.
Coadministration of an anti-IL-10 Receptor (R) monoclo-
nal antibody (mAb) with CpG induces more severe disease
characterized also by hemophagocytosis (fulminant sHLH).
Objectives
We evaluated whether the neutralization of IFNg in murin
sHLH and fulminant sHLH affected the disease features
and we investigated whether treatment with an anti-IFNg
mAb affected the clinical and laboratory features in
murine models of sHLH and fulminant sHLH; we also
exploited the in vivo principle that, in the presence of an
anti-IFNg antibody, circulating IFNg bound to the
antibody is incorporated in a complex leading to accumu-
lation of the cytokine in serum, therefore allowing the
quantification of IFNg production.
Methods
C57BL/6 mice received i.p. injections of CpG on days 0,
2, 4, 7 & 9. Neutralizing IL-10R, mAb 1B1.3A at
200 µg/mouse (days 0,2,4,6), and anti-mouse IFNg, mAb
XMG1.2 at 100 mg/kg (days 1, 3, 6) were administered i.v..
Results
In murine sHLH, the neutralization of IFNg caused a
reduction in body weight loss and splenomegaly, nor-
malized white blood cell counts and hyperferritinemia,
and corrected anemia. Blockade of IFNg in mice with
fulminant sHLH improved key disease features by
decreasing the body weight loss by 20%, reduced spleno-
megaly by 23%, improved anemic parameters by 13%,
reversed cytopenia by 30% and normalized sHLH-
associated cytokine storm as evidenced by a 60%
decrease in circulating levels of TNFa. Circulating levels
of IFNg reached steady state at 250 ng/ml in both models
(sHLH and fulminant sHLH). Expression of IFNg-
induced inflammatory genes demonstrated that spleen
and liver are major sites of IFNg production.
Conclusion
Neutralization of IFNg appears to effectively improve
the clinical and laboratory features in the CpG-induced
models of sHLH, including fulminant sHLH. These data
offer a rationale for the neutralization of IFNg as a
potential targeted therapeutic approach in patients with
severe form of sHLH.
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